DEBRA research invests in Topadur to advance small-molecule therapies for dystrophic Epidermolysis bullosa

The Medical News ·
Health & Medicine United Kingdom

DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced an investment by DEBRA Research in Topadur to support a preclinical program exploring a new treatment approach for dystrophic Epidermolysis bullosa (DEB). DEB is one of…

Read original article on The Medical News →

Related news